David Shaw’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.24M | Buy |
30,883
+29,821
| +2,808% | +$6.97M | ﹤0.01% | 1993 |
|
|
2026
Q1 | $243K | Sell |
1,062
-124,706
| -99% | -$28M | ﹤0.01% | 4143 |
|
|
2025
Q4 | $26.8M | Buy |
125,768
+122,182
| +3,407% | +$25.2M | 0.01% | 1050 |
|
|
2025
Q3 | $713K | Sell |
3,586
-3,600
| -50% | -$671K | ﹤0.01% | 3668 |
|
|
2025
Q2 | $1.24M | Sell |
7,186
-13,340
| -65% | -$2.17M | ﹤0.01% | 3083 |
|
|
2025
Q1 | $3.2M | Sell |
20,526
-17,454
| -46% | -$2.49M | ﹤0.01% | 2241 |
|
|
2024
Q4 | $5.23M | Sell |
37,980
-52,400
| -58% | -$6.89M | ﹤0.01% | 1944 |
|
|
2024
Q3 | $13.5M | Sell |
90,380
-191,157
| -68% | -$25.8M | 0.01% | 1227 |
|
|
2024
Q2 | $38.4M | Sell |
281,537
-58,581
| -17% | -$7.97M | 0.04% | 554 |
|
|
2024
Q1 | $51.4M | Buy |
340,118
+74,961
| +28% | +$10.7M | 0.04% | 470 |
|
|
2023
Q4 | $33.4M | Buy |
265,157
+44,604
| +20% | +$4.45M | 0.03% | 631 |
|
|
2023
Q3 | $20.7M | Buy |
220,553
+88,470
| +67% | +$8.28M | 0.02% | 834 |
|
|
2023
Q2 | $11.8M | Sell |
132,083
-7,133
| -5% | -$621K | 0.01% | 1215 |
|
|
2023
Q1 | $14.9M | Buy |
139,216
+22,512
| +19% | +$2.58M | 0.02% | 1083 |
|
|
2022
Q4 | $14.3M | Buy |
116,704
+24,894
| +27% | +$2.89M | 0.02% | 1143 |
|
|
2022
Q3 | $9.48M | Sell |
91,810
-7,972
| -8% | -$756K | 0.01% | 1393 |
|
|
2022
Q2 | $9.28M | Sell |
99,782
-52,177
| -34% | -$4.92M | 0.01% | 1460 |
|
|
2022
Q1 | $17.8M | Sell |
151,959
-2,661
| -2% | -$308K | 0.02% | 1115 |
|
|
2021
Q4 | $20.8M | Buy |
154,620
+129,793
| +523% | +$19.3M | 0.02% | 1064 |
|
|
2021
Q3 | $3.96M | Buy |
24,827
+18,710
| +306% | +$2.56M | ﹤0.01% | 2344 |
|
|
2021
Q2 | $805K | Sell |
6,117
-2,250
| -27% | -$300K | ﹤0.01% | 3724 |
|
|
2021
Q1 | $1.08M | Sell |
8,367
-14,241
| -63% | -$2.16M | ﹤0.01% | 3055 |
|
|
2020
Q4 | $3.77M | Buy |
22,608
+6,243
| +38% | +$1.03M | ﹤0.01% | 2088 |
|
|
2020
Q3 | $2.52M | Sell |
16,365
-3,781
| -19% | -$543K | ﹤0.01% | 2219 |
|
|
2020
Q2 | $2.98M | Buy |
20,146
+147
| +0.7% | +$20.2K | ﹤0.01% | 2087 |
|
|
2020
Q1 | $2.25M | Buy |
19,999
+17,750
| +789% | +$2.31M | ﹤0.01% | 2065 |
|
|
2019
Q4 | $313K | Sell |
2,249
-12,573
| -85% | -$1.4M | ﹤0.01% | 3609 |
|
|
2019
Q3 | $1.43M | Sell |
14,822
-2,163
| -13% | -$241K | ﹤0.01% | 2604 |
|
|
2019
Q2 | $1.96M | Sell |
16,985
-241,192
| -93% | -$28.9M | ﹤0.01% | 2254 |
|
|
2019
Q1 | $30.4M | Buy |
258,177
+211,996
| +459% | +$18.6M | 0.04% | 537 |
|
|
2018
Q4 | $2.89M | Buy |
46,181
+5,881
| +15% | +$370K | ﹤0.01% | 1874 |
|
|
2018
Q3 | $2.86M | Buy |
40,300
+20,377
| +102% | +$1.4M | ﹤0.01% | 1952 |
|
|
2018
Q2 | $1.32M | Buy |
19,923
+14,381
| +259% | +$946K | ﹤0.01% | 2513 |
|
|
2018
Q1 | $362K | Buy |
+5,542
| New | +$311K | ﹤0.01% | 3050 |
|
Other funds holding ASND
RCM
ACA
JT
David Shaw's ASND Position: Q2 2026 in Review
David Shaw increased its Ascendis Pharma A/S (ASND) stake by 2,808% in Q2 2026, buying an estimated $6.97M and bringing the position to 30,883 shares worth $8.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1993.
David Shaw first reported a position in ASND in Q1 2018 and has held it in 34 quarters since. The position peaked at $51.4M in Q1 2024. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- David Shaw held 30,883 shares of Ascendis Pharma A/S worth $8.24M as of Q2 2026.
- David Shaw bought 29,821 Ascendis Pharma A/S shares in Q2 2026, an estimated $6.97M.
- Ascendis Pharma A/S made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #1993 holding.
- David Shaw first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 34 quarters since.
- David Shaw's Ascendis Pharma A/S position peaked at $51.4M in Q1 2024.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.